Birchview Capital’s Soleno Therapeutics SLNO Stock Holding History

Birchview Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-245,127	Closed	-$1.05M	–	52
2023 Q2	$1.05M	Hold	245,127	–	–	0.79%	22
2023 Q1	$525K	Hold	245,127	–	–	0.41%	33
2022 Q4	$485K	Hold	245,127	–	–	0.34%	35
2022 Q3	$409K	Hold	245,127	–	–	0.29%	42
2022 Q2	$680K	Hold	245,127	–	–	0.49%	29
2022 Q1	$820K	Buy	245,127 +186,667	+319%	+$967K	0.59%	31
2021 Q4	$360K	Hold	58,460	–	–	0.23%	50
2021 Q3	$811K	Hold	58,460	–	–	0.55%	32
2021 Q2	$1M	Hold	58,460	–	–	0.6%	30
2021 Q1	$1.1M	Buy	58,460 +3,333	+6%	+$107K	0.66%	25
2020 Q4	$1.6M	Hold	55,127	–	–	0.92%	19
2020 Q3	$2.08M	Hold	55,127	–	–	1.39%	12
2020 Q2	$1.84M	Buy	55,127 +41,694	+310%	+$1.81M	1.11%	13
2020 Q1	$480K	Sell	13,433 -20,607	-61%	-$877K	0.43%	29
2019 Q4	$1.5M	Buy	34,040 +18,000	+112%	+$460K	1.09%	11
2019 Q3	$361K	Hold	16,040	–	–	0.24%	34
2019 Q2	$674K	Hold	16,040	–	–	0.41%	26
2019 Q1	$496K	Sell	16,040 -27,733	-63%	-$737K	0.31%	30
2018 Q4	$1.12M	Hold	43,773	–	–	1.06%	10
2018 Q3	$1.42M	Sell	43,773 -1,456	-3%	-$52.9K	0.92%	11
2018 Q2	$1.59M	Hold	45,229	–	–	1.08%	12
2018 Q1	$1.23M	Hold	45,229	–	–	0.81%	13
2017 Q4	$1.03M	Buy	+45,229	New	+$1.3M	0.6%	14

Other funds holding SLNO

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Birchview Capital's SLNO Position: Q3 2023 in Review

Birchview Capital sold out of Soleno Therapeutics (SLNO) in Q3 2023, closing a stake of 245,127 shares — an estimated $1.05M sold.

Birchview Capital first reported a position in SLNO in Q4 2017 and held it in 23 quarters. The position peaked at $2.08M in Q3 2020. 54 funds tracked by Wall St. Rank hold SLNO as of Q3 2023.

Birchview Capital reported no remaining Soleno Therapeutics position as of Q3 2023 after selling out during the quarter.
Birchview Capital sold 245,127 Soleno Therapeutics shares in Q3 2023, an estimated $1.05M.
Birchview Capital first reported a position in Soleno Therapeutics in Q4 2017 and held it in 23 quarters.
Birchview Capital's Soleno Therapeutics position peaked at $2.08M in Q3 2020.
54 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2023.

Based on Birchview Capital's 13F filing for Q3 2023, filed 14 Nov 2023.